本次独道获得NMPA批准，是本集团引领全球手术机器人领域技术与应用发展的里程碑式突破，也标志 着国产手术机器人在微无创诊疗关键技术路径上实现系统性全覆盖。至此，本集团在手术机器人领域获 批上市的产品数量增至7款，成为全球首家、也是目前唯一一家实现手术机器人"五大黄金赛道"全赛道 产品商业化上市的企业。 据介绍，最新获批的独道是一个无创经自然腔道机器人手术平台，其具有超柔顺，超纤细蛇形机器人导 管，可通过人体自然腔道，以无体表创伤的方式进入难以触及的狭窄病灶空间，对肺部微小结节等癌症 早期病变的早诊早治具有重要意义。 微创机器人-B(02252)涨超7%，截至发稿，涨7.64%，报22.58港元，成交额2045.01万港元。 消息面上，12月24日，微创机器人-B发布公告，由本集团自主研发的支气管镜手术机器人独道 UniPathTM电子支气管镜手术导航系统(独道)正式获得国家药品监督管理局(NMPA)批准。 ...

Group 1 - The core viewpoint of the news is that MicroPort Robotics has received approval from the National Medical Products Administration (NMPA) for its self-developed bronchoscopic surgical robot, UniPathTM, marking a significant milestone in the field of surgical robotics and indicating comprehensive coverage of key technologies in minimally invasive diagnosis and treatment [1] - With this approval, the number of surgical robot products approved for market by the company has increased to seven, making it the first and only company globally to commercialize products across all five major categories of surgical robots [1] - The newly approved UniPathTM is a non-invasive robotic surgical platform that utilizes a highly flexible, slender robotic catheter to access hard-to-reach narrow lesions through natural body cavities, which is crucial for the early diagnosis and treatment of early-stage lung cancer [1] Group 2 - As a representative of natural orifice transluminal endoscopic surgery (NOTES) robots, the bronchoscopic surgical robot is seen as a key technological pathway for advancing minimally invasive surgery towards "less trauma and no external incisions" [2] - UniPathTM integrates critical technologies such as precise robotic control, flexible catheter navigation, intelligent path planning, and closed-loop control, providing a comprehensive solution for complex pulmonary anatomy [2] - The system enhances accessibility to fine bronchi and deep lung segments, supporting higher certainty in reaching and performing puncture and ablation operations on small lesions under dynamic breathing conditions, thereby continuously expanding the clinical application boundaries of bronchoscopic interventions [2]

Core Insights - The company, MicroPort Robotics-B (02252.HK), has received approval from the National Medical Products Administration (NMPA) for its self-developed bronchoscopic surgical robot, UniPathTM, marking a significant milestone in the field of surgical robotics [1] - This approval increases the number of products approved for market by the company in the surgical robotics sector to seven, making it the first and only company globally to commercialize products across all five major categories of surgical robots [1] - The newly approved UniPathTM is a non-invasive robotic surgical platform that utilizes a highly flexible, slender robotic catheter to access hard-to-reach areas within the body through natural orifices, which is crucial for early diagnosis and treatment of small lung nodules and early-stage cancers [1] Industry Insights - As a representative of natural orifice surgical robots, bronchoscopic surgical robots are seen as a key technological pathway for advancing minimally invasive surgery towards "less trauma and no external incisions" [2] - UniPathTM integrates critical technologies such as precise robotic control, flexible catheter navigation, intelligent path planning, and closed-loop control, providing a comprehensive solution for complex pulmonary anatomy [2] - The system enhances accessibility to fine bronchi and deep lung segments, supporting higher certainty in reaching and performing puncture and ablation operations on small lesions under dynamic respiratory conditions, thereby expanding the clinical application boundaries of bronchoscopic interventions [2]